Virtual Screening and Biological Evaluation of Novel Low Molecular Weight Protein Tyrosine Phosphatase Inhibitor for the Treatment of Insulin Resistance

References

• Zhang ZY. Drugging the undruggable: therapeutic potential of targeting protein tyrosine phosphatases. Acc Chem Res. 2017;50(1):122–129. doi:10.1021/acs.accounts.6b00537
   PubMed Web of Science ®Google Scholar
• Tonks NK. Protein tyrosine phosphatases: from genes, to function, to disease. Nat Rev Mol Cell Biol. 2006;7:833–846. doi:10.1038/nrm2039
   PubMed Web of Science ®Google Scholar
• Vainonen JP, Momeny M, Westermarck J. Druggable cancer phosphatases. Sci Transl Med. 2021;13(588):588. doi:10.1126/scitranslmed.abe2967
   Web of Science ®Google Scholar
• Stanford SM, Collins M, Diaz MA, et al. The low molecular weight protein tyrosine phosphatase promotes adipogenesis and subcutaneous adipocyte hypertrophy. J Cell Physiol. 2021;236(9):6630–6642. doi:10.1002/jcp.30307
   PubMed Web of Science ®Google Scholar
• Kousaxidis A, Petrou A, Lavrentaki V, Fesatidou M, Nicolaou I, Geronikaki A. Aldose reductase and protein tyrosine phosphatase 1B inhibitors as a promising therapeutic approach for diabetes mellitus. Eur J Med Chem. 2020;207:112742. doi:10.1016/j.ejmech.2020.112742
   PubMed Web of Science ®Google Scholar
• Nandi S, Saxena M. Potential inhibitors of Protein Tyrosine Phosphatase (PTP1B) Enzyme: promising target for type-II diabetes mellitus. Curr Top Med Chem. 2020;20(29):2692–2707. doi:10.2174/1568026620999200904121432
   PubMed Web of Science ®Google Scholar
• Montresor A, Toffali L, Fumagalli L, et al. Activation of protein tyrosine phosphatase receptor type gamma suppresses mechanisms of adhesion and survival in chronic lymphocytic leukemia cells. J Immunol. 2021;207(2):671–684. doi:10.4049/jimmunol.2001462
   PubMed Web of Science ®Google Scholar
• Yu ZH, Zhang ZY. Regulatory mechanisms and novel therapeutic targeting strategies for protein tyrosine phosphatases. Chem Rev. 2018;118:1069–1091. doi:10.1021/acs.chemrev.7b00105
   PubMed Web of Science ®Google Scholar
• Singh S, Singh Grewal A, Grover R, et al. Recent updates on development of protein-tyrosine phosphatase 1B inhibitors for treatment of diabetes, obesity and related disorders. Bioorg Chem. 2022;121:105626. doi:10.1016/j.bioorg.2022.105626
   PubMed Web of Science ®Google Scholar
• Sharma C, Kim Y, Ahn D, Chung SJ. Protein tyrosine phosphatases (PTPs) in diabetes: causes and therapeutic opportunities. Arch Pharm Res. 2021;44:310–321. doi:10.1016/j.bioorg.2022.105626
   PubMed Web of Science ®Google Scholar
• Crunkhorn S. Metabolic disease: protein tyrosine phosphatase inhibitor reverses diabetes. Nat Rev Drug Discov. 2017;16(5):312–313. doi:10.1038/nrd.2017.73
   PubMed Web of Science ®Google Scholar
• He RJ, Yu ZH, Zhang RY, Zhang ZY. Protein tyrosine phosphatases as potential therapeutic targets. Acta Pharmacol Sin. 2014;35:1227–1246. doi:10.1038/aps.2014.80
   PubMed Web of Science ®Google Scholar
• Pandey SK, Yu XX, Watts LM, et al. Reduction of low molecular weight protein-tyrosine phosphatase expression improves hyperglycemia and insulin sensitivity in obese mice. J Biol Chem. 2007;282(19):14291–14299. doi:10.1074/jbc.M609626200
   PubMed Web of Science ®Google Scholar
• Ottana R, Maccari R, Ciurleo R, et al. 5-Arylidene-2-phenylimino-4-thiazolidinones as PTP1B and LMW-PTP inhibitors. Bioorg Med Chem. 2009;17(5):1928–1937. doi:10.1016/j.bmc.2009.01.044
   PubMed Web of Science ®Google Scholar
• DeSouza SR, Olson MC, Tinucci SL, et al. SAR of non-hydrolysable analogs of pyridoxal 5’-phosphate against low molecular weight protein tyrosine phosphatase isoforms. Bioorg Med Chem Lett. 2020;30:127342. doi:10.1016/j.bmcl.2020.127342
   PubMed Web of Science ®Google Scholar
• Maccari R, Ottanà R. Low molecular weight phosphotyrosine protein phosphatases as emerging targets for the design of novel therapeutic agents. J Med Chem. 2012;55(1):2–22. doi:10.1021/jm200607g
   PubMed Web of Science ®Google Scholar
• He R, Wang J, Yu ZH, et al. Inhibition of low molecular weight protein tyrosine phosphatase by an induced-fit mechanism. J Med Chem. 2016;59:9094–9106. doi:10.1021/acs.jmedchem.6b00993
   PubMed Web of Science ®Google Scholar
• Forghieri M, Laggner C, Paoli P, et al. Synthesis, activity and molecular modeling of a new series of chromones as low molecular weight protein tyrosine phosphatase inhibitors. Bioorg Med Chem. 2009;17(7):2658–2672. doi:10.1016/j.bmc.2009.02.060
   PubMed Web of Science ®Google Scholar
• Vidal D, Blobel J, Perez Y, Thormann M, Pons M. Structure-based discovery of new small molecule inhibitors of low molecular weight protein tyrosine phosphatase. Eur J Med Chem. 2007;42(8):1102–1108. doi:10.1016/j.ejmech.2007.01.017
   PubMed Web of Science ®Google Scholar
• Stanford SM, Diaz MA, Ardecky RJ, et al. Discovery of orally bioavailable purine-based inhibitors of the low-molecular-weight protein tyrosine phosphatase. J Med Chem. 2021;64(9):5645–5653. doi:10.1021/acs.jmedchem.0c02126
   PubMed Web of Science ®Google Scholar
• Stanford SM, Aleshin AE, Zhang V, et al. Diabetes reversal by inhibition of the low-molecular-weight tyrosine phosphatase. Nat Chem Biol. 2017;13:624–632. doi:10.1038/nchembio.2344
   PubMed Web of Science ®Google Scholar
• Lian X, Xia Z, Li X, et al. Anti-MRSA drug discovery by ligand-based virtual screening and biological evaluation. Bioorg Chem. 2021;114:105042. doi:10.1016/j.bioorg.2021.105042
   PubMed Web of Science ®Google Scholar
• Jahan S, Redhu NS, Siddiqui AJ, et al. Nobiletin as a neuroprotectant against NMDA receptors: an in silico approach. Pharmaceutics. 2022;14(6):1123. doi:10.3390/pharmaceutics14061123
   PubMed Web of Science ®Google Scholar
• Witten MR, Wissler L, Snow M, et al. X-ray characterization and structure-based optimization of striatal-enriched protein tyrosine phosphatase inhibitors. J Med Chem. 2017;60(22):9299–9319. doi:10.1021/acs.jmedchem.7b01292
   PubMed Web of Science ®Google Scholar
• Kong Q, Li G, Zhang F, et al. N-arylimidazoliums as highly selective biomimetic antimicrobial agents. J Med Chem. 2022;65:11309–11321. doi:10.1021/acs.jmedchem.2c00818
   PubMed Web of Science ®Google Scholar
• Xie YP, Sangaraiah N, Meng JP, Zhou CH. Unique carbazole-oxadiazole derivatives as new potential antibiotics for combating gram-positive and -negative bacteria. J Med Chem. 2022;65(8):6171–6190. doi:10.1021/acs.jmedchem.2c00001
   PubMed Web of Science ®Google Scholar
• Zhang Q, Kong X, Yuan H, Guan H, Li Y, Niu Y. Mangiferin improved palmitate-induced-insulin resistance by promoting free fatty acid metabolism in HepG2 and C2C12 cells via PPARalpha: mangiferin improved insulin resistance. J Diabetes Res. 2019;2019:2052675. doi:10.1155/2019/2052675
   PubMed Web of Science ®Google Scholar
• Zhou X, Wang LL, Tang WJ, Tang B. Astragaloside IV inhibits protein tyrosine phosphatase 1B and improves insulin resistance in insulin-resistant HepG2 cells and triglyceride accumulation in oleic acid (OA)-treated HepG2 cells. J Ethnopharmacol. 2021;268:113556. doi:10.1016/j.jep.2020.113556
   PubMed Web of Science ®Google Scholar